TY - JOUR
T1 - Arsenic compounds activate the MAPK and caspase pathways to induce apoptosis in OEC-M1 gingival epidermal carcinoma
AU - Foo, Ning Ping
AU - Ko, Chi Lin
AU - Chu, Chiao Yun
AU - Wang, Chia Yih
AU - So, Edmund Cheung
AU - Huang, Bu Miin
N1 - Funding Information:
The present study was supported by the Ministry of Science and Technology of Taiwan, R.O.C (grant no. MOST106-2811-B-006-014, to BMH) and An-Nan Hospital, Taiwan, R.O.C (grant no. ANHRF108-20, to NPF, CLK, ECS and BMH).
Publisher Copyright:
© 2020 Spandidos Publications. All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Arsenic is a well-documented environmental toxicant that can induce neurotoxicity and peripheral vascular diseases. In fact, arsenic trioxide has been used to treat various cancer types. Oral cancer has been in the top ten common cancers for decades in Taiwan, and the incidence rate is continuously increasing. The majority of oral cancers are associated with excessive tobacco, alcohol consumption and betel chewing. To the best of our knowledge, no study has revealed the effect of arsenic compounds on oral cancers. Thus, the present study used OEC-M1 oral squamous carcinoma cells treated with sodium arsenite (NaAsO2) and dimethylarsenic acid (DMA) to determine whether both arsenic compounds could exert anticancer effects on oral cancer. The results demonstrated that NaAsO2and DMA induced rounding up and membrane blebbing in OEC-M1 cells, which are morphological characteristics of apoptosis. Annexin V/PI double staining analysis further confirmed that both arsenic compounds induced apoptosis of OEC-M1 cells. In addition, NaAsO2and DMA significantly decreased the survival rate and increased the percentage of OEC-M1 cells in the subG1 and G2/M phases (P<0.05). Furthermore, both arsenic compounds significantly activated the cleavage of caspase-8, -9, -3 and PARP, and the phosphorylation of JNK, ERK1/2 and p38 in OEC-M1 cells (P<0.05). Collectively, the findings of the present study indicated that NaAsO2and DMA stimulate extrinsic and intrinsic apoptotic pathways through the activation of the MAPK pathways to induce apoptosis of OEC-M1 cells, suggesting that NaAsO2and DMA may be used as novel anticancer drugs for oral cancers.
AB - Arsenic is a well-documented environmental toxicant that can induce neurotoxicity and peripheral vascular diseases. In fact, arsenic trioxide has been used to treat various cancer types. Oral cancer has been in the top ten common cancers for decades in Taiwan, and the incidence rate is continuously increasing. The majority of oral cancers are associated with excessive tobacco, alcohol consumption and betel chewing. To the best of our knowledge, no study has revealed the effect of arsenic compounds on oral cancers. Thus, the present study used OEC-M1 oral squamous carcinoma cells treated with sodium arsenite (NaAsO2) and dimethylarsenic acid (DMA) to determine whether both arsenic compounds could exert anticancer effects on oral cancer. The results demonstrated that NaAsO2and DMA induced rounding up and membrane blebbing in OEC-M1 cells, which are morphological characteristics of apoptosis. Annexin V/PI double staining analysis further confirmed that both arsenic compounds induced apoptosis of OEC-M1 cells. In addition, NaAsO2and DMA significantly decreased the survival rate and increased the percentage of OEC-M1 cells in the subG1 and G2/M phases (P<0.05). Furthermore, both arsenic compounds significantly activated the cleavage of caspase-8, -9, -3 and PARP, and the phosphorylation of JNK, ERK1/2 and p38 in OEC-M1 cells (P<0.05). Collectively, the findings of the present study indicated that NaAsO2and DMA stimulate extrinsic and intrinsic apoptotic pathways through the activation of the MAPK pathways to induce apoptosis of OEC-M1 cells, suggesting that NaAsO2and DMA may be used as novel anticancer drugs for oral cancers.
UR - http://www.scopus.com/inward/record.url?scp=85094957322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094957322&partnerID=8YFLogxK
U2 - 10.3892/or.2020.7793
DO - 10.3892/or.2020.7793
M3 - Article
C2 - 33125114
AN - SCOPUS:85094957322
SN - 1021-335X
VL - 44
SP - 2701
EP - 2714
JO - Oncology Reports
JF - Oncology Reports
IS - 6
ER -